Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOBID vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing c AMP, and blocking adenosine receptors. It also has anti-inflammatory and immunomodulatory effects.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity,Off-label: Adjuvant in treatment of obstructive sleep apnea
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
Theophylline extended-release capsules: 300-600 mg/day orally divided every 12 hours. Initial dose 300 mg/day, titrate based on serum concentrations (target 10-20 mcg/m L). Max 600 mg/day unless serum levels monitored.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Neonates: 24-36 h; Children (1-9 y): 3-4 h; Adults (non-smokers): 6-12 h; Adults (smokers): 4-5 h; Hepatic cirrhosis: prolonged (up to 30 h); Heart failure: prolonged (up to 20 h).
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Primarily hepatic via CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Exhibits saturable (nonlinear) pharmacokinetics at high doses.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Renal (10% unchanged), hepatic metabolism (90%, primarily via CYP1A2 and CYP3A4); 20% excreted in feces as metabolites.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
40-60% (primarily to albumin). Decreased binding in neonates, hepatic disease, and uremia.
55–65% bound to plasma proteins, primarily albumin.
0.45 L/kg (range: 0.3-0.7 L/kg). Higher in neonates (0.7-0.9 L/kg). Represents distribution throughout total body water.
0.4–0.6 L/kg, indicating distribution into total body water.
Oral: 96-100% (immediate release); Sustained release (THEOBID): ~100% (bioequivalent to immediate release at steady state); IV: 100%; Rectal: ~80-100%.
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
No specific GFR-based dose adjustment for theophylline. However, accumulation may occur in severe renal impairment; monitor serum levels and adjust dose to achieve therapeutic concentrations (10-20 mcg/m L).
No dose adjustment required for renal impairment.
Child-Pugh Class A: Reduce dose by 50%. Child-Pugh Class B or C: Reduce dose by 75% or use alternative. Monitor serum concentrations closely.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
For asthma: Oral immediate-release: 5 mg/kg/day divided q6-8h. Extended-release: 10-20 mg/kg/day divided q12h (max 600 mg/day). Target serum concentration 5-15 mcg/m L. Dosing based on age and weight, titrate slowly.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Elderly patients (>60 years) often have reduced clearance. Start with 300 mg/day orally extended-release, titrate slowly to lowest effective dose. Monitor serum concentrations closely to avoid toxicity (target 5-15 mcg/m L).
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
No FDA black box warning.
No FDA black box warning exists for this drug.
Risk of serious cardiovascular toxicity (arrhythmias, seizures, death) especially at serum levels >20 mcg/m L,Cautious use in patients with peptic ulcer, seizure disorders, cardiac disease, hepatic impairment,Monitor serum theophylline levels to avoid toxicity,Reduce dose in smokers and with drugs that induce CYP1A2 (e.g., phenytoin, rifampin),Avoid in patients with active peptic ulcer or uncontrolled seizure disorders
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to theophylline or any component of the formulation,Active peptic ulcer disease,Uncontrolled seizure disorders
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
High-fat meals can increase absorption of sustained-release formulations. Charcoal-broiled foods and a high-protein, low-carbohydrate diet can increase theophylline clearance. Avoid concurrent ingestion of caffeine-containing foods/beverages.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
Theophylline (THEOBID) is not considered a major teratogen. First trimester: Limited data show no significant increase in congenital malformations. Second and third trimesters: No known structural effects; fetal tachycardia and irritability may occur due to maternal toxicity. Neonatal withdrawal (jitteriness, vomiting) reported with third-trimester use.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels may reach therapeutic concentrations, especially in preterm neonates. Risk of irritability, jitteriness, and feeding problems. Benefit of breastfeeding should be weighed against potential adverse effects; monitor infant for theophylline toxicity.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
Pregnancy increases theophylline clearance due to elevated cardiac output and increased hepatic metabolism, particularly in the second and third trimesters. Dose may need to be increased by 30-50% to maintain therapeutic levels. Postpartum, clearance decreases; dose should be reduced to prepregnancy levels within 2 weeks to avoid toxicity. Monitor serum levels and adjust accordingly.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
Theophylline levels must be monitored; narrow therapeutic index (5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders. Use with caution in heart failure, hepatic impairment, and elderly. Many drug interactions (e.g., cimetidine, fluoroquinolones, macrolides) increase levels. Smoking induces metabolism, requiring higher doses.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Take exactly as prescribed; do not change dose without consulting doctor.,Do not crush or chew sustained-release capsules.,Avoid excessive caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Report symptoms like nausea, vomiting, palpitations, insomnia, or seizures.,Notify doctor if you start or stop smoking, or if you are prescribed new medications.,Keep regular appointments for blood level monitoring.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOBID vs AEROLATE SR, answered by our medical review team.
THEOBID is a Bronchodilator that works by Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing c AMP, and blocking adenosine receptors. It also has anti-inflammatory and immunomodulatory effects.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOBID and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOBID is: Theophylline extended-release capsules: 300-600 mg/day orally divided every 12 hours. Initial dose 300 mg/day, titrate based on serum concentrations (target 10-20 mcg/m L). Max 600 mg/day unless serum levels monitored.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOBID and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOBID is classified as Category C. Theophylline (THEOBID) is not considered a major teratogen. First trimester: Limited data show no significant increase in congenital malformations. Second and third trimesters: No . AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.